Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,261 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 3,261 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the transaction, the insider directly owned 223,640 shares in the company, valued at $5,103,464.80. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Pacira BioSciences Trading Up 2.5%

Shares of NASDAQ PCRX traded up $0.55 during midday trading on Thursday, reaching $22.57. The company had a trading volume of 647,582 shares, compared to its average volume of 927,843. The stock has a market cap of $913.86 million, a PE ratio of 150.47 and a beta of 0.21. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.64. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54. The firm’s fifty day moving average price is $21.79 and its 200-day moving average price is $23.56.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). The firm had revenue of $196.87 million during the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.91 EPS. On average, equities research analysts anticipate that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

Institutional Trading of Pacira BioSciences

Large investors have recently modified their holdings of the company. Vident Advisory LLC increased its holdings in Pacira BioSciences by 15.0% during the fourth quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock valued at $610,000 after buying an additional 3,075 shares during the last quarter. Empowered Funds LLC grew its position in shares of Pacira BioSciences by 1.9% during the 4th quarter. Empowered Funds LLC now owns 227,605 shares of the company’s stock valued at $5,890,000 after acquiring an additional 4,167 shares during the period. XTX Topco Ltd purchased a new stake in shares of Pacira BioSciences in the 4th quarter worth $2,146,000. Millennium Management LLC raised its holdings in Pacira BioSciences by 73.3% in the 4th quarter. Millennium Management LLC now owns 122,606 shares of the company’s stock worth $3,173,000 after purchasing an additional 51,848 shares during the period. Finally, Inspire Investing LLC lifted its position in Pacira BioSciences by 3.2% during the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock valued at $465,000 after purchasing an additional 556 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

PCRX has been the subject of several research analyst reports. Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a research note on Monday, December 29th. Barclays initiated coverage on Pacira BioSciences in a report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Hold” and an average target price of $30.75.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.